# Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

> **NCT00005037** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** temozolomide
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00005037
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2002-10
- **Final completion:** 2008-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005037, "Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00005037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*